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http://dx.doi.org/10.1016/j.jacl.2013.03Abstract: Low-density lipoprotein (LDL)-apheresis is a Food and Drug Administration–approved treat-
ment for patients with homozygous familial hypercholesterolemia (FH) or severe heterozygous FH.
Based on electrochemical principles, it selectively removes apolipoprotein B–containing lipoproteins
through extracorporeal precipitation with either heparin (Heparin-induced Extracorporeal LDL Precip-
itation, ie, HELP) or dextran sulfate (Liposorber). LDL-apheresis can lead to an acute decrease in LDL
cholesterol (LDL-C) of 70%–80%, but there is a rapid rebound to baseline levels within approximately
2 weeks. LDL-apheresis is typically performed once-a-week in patients with homozygous FH and ev-
ery other week in those with heterozygous FH to produce time-average LDL-C reductions of w40%.
Side effects associated with LDL-apheresis include hypotension (later found to be due to concomitant
use of angiotensin-converting enzyme inhibitors), nausea/vomiting, flushing, angina, and fainting.
Posttreatment bleeding can occur secondary to heparin used during the procedure. Challenges associ-
ated with LDL-apheresis include vascular access often requiring an arteriovenous fistula (fistulas may
clot and require revision over time), the time associated with each treatment session (2–4 hours), the
frequency of treatment, and the scarcity of medical centers which perform LDL-apheresis. Given the
nature of LDL-apheresis, randomized placebo controlled trials are nearly impossible, and virtually all
studies of clinical benefit have been non-randomized investigations of small numbers of subjects.
Nonetheless, results from those studies support the benefits of LDL-C reduction for reducing coronary
atherosclerosis and cardiovascular events.
 2013 National Lipid Association. All rights reserved.Familial hypercholesterolemia (FH) is a disease caused
by defects in the genes coding for the low-density lipopro-
tein (LDL) receptor, apolipoprotein (Apo) B, or proprotein
convertase subtilisin/kexin type 9.1 FH is characterized by
severely elevated serum cholesterol concentrations, and
physical examination may reveal xanthelasmas, tendonil.com
epted for publication March 18,
National Lipid Association. All right
.002xanthomas, tuberous xanthomas, and corneal arcus.1,2 FH
should be suspected in adults with an LDL-cholesterol
(LDL-C) concentration $190 mg/dL, and in children
with LDL-C $160 mg/dL. Homozygous FH is rare, occur-
ring in approximately one of every million persons (w333
individuals in the United States). Heterozygous FH is more
common, occurring in one of every 500 people (w620,000
in the United States). Average LDL-C level in untreated ho-
mozygotes, as reported by Goldstein et al3, was 625 mg/dL,
298 mg/dL in untreated heterozygote adults, and 241 mg/dL
in heterozygote children. Although many patients with
heterozygous FH respond well to high-dose statins,s reserved.
Figure 1 Time–course effect of LDL-apheresis on lipid levels.
A, immediately after apheresis; B, immediately before apheresis;
TC, total cholesterol.  Copyright Kaneka Pharma America, LLC
2010. This figure was reprinted with permission from Kaneka
Pharma America, LLC. A, immediatley after apheresis; B, im-
mediately before apheresis; LDL-C, low-density lipoprotein
cholesterol; Lp(a), lipoprotein (a); TC, total cholesterol.
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mozygous FH patients is difficult because of the magnitude
of LDL-C reduction that is needed, and because many ho-
mozygotes are refractory to statins, the mechanism of ac-
tion of which depends mainly on up-regulation of LDL
receptors.
A young patient who brought FH to public attention in
the 1980s was a girl who was diagnosed with homozygous
FH at the age of six.4 The timing of this diagnosis was
rather late compared with present standards. Usually diag-
nosis is made around the age of 2 years. The typical course
of events is that a child with xanthomas is seen by a pedi-
atrician who then sends the patient to a dermatologist. An
astute dermatologist will perform a lipid profile, and an el-
evated LDL-C level then prompts a referral to a cardiolo-
gist, or, more appropriately, a lipidologist. In the case of
this 6-year old diagnosed with FH, her total-C concentra-
tion was 1200 mg/dL, and LDL-C was 1130 mg/dL. During
the year of her diagnosis, she underwent two separate cor-
onary artery bypass procedures, suffered from heart failure,
and underwent a combined heart–liver transplantation, after
which, her total-C concentration decreased to 250 mg/dL.
However, at the age of 12 years and 9 months, she died af-
ter rejection of a second transplant. Transplants are no lon-
ger routinely suggested for children or adults with
homozygous FH, not only because of issues of rejection,
but also because of the risk for malignancy associated
with long-term use of immunosuppressive agents.5
LDL-apheresis is another treatment option for patients
with homozygous FH or severe heterozygous FH.6 The pro-
cess involves the selective removal of Apo B–containing lip-
oproteins eg, very-low-density lipoprotein (VLDL), LDL,
and lipoprotein (a) [Lp(a)], through Heparin-induced Extra-
corporeal LDL Precipitation (HELP; B. Braun Avitum AG,
Glandorf, Germany: http://www.bbraun.com/cps/rde/xchg/
bbraun-com/hs.xsl/apheresis-01.html#2)7 or extracorporeal
precipitation with dextran sulfate (Liposorber; KanekaMed-
ical Products, New York, NY: http://www.liposorber.com/
home1.htm).8 LDL-apheresis produces an acute decrease
in LDL-C levels of 70%–80%, but there is a rapid rebound
and concentrations return to initial levels by w2 weeks
(Fig. 1). Lp(a) concentration also declines by 50%–80%
acutely. Individuals with significant hypertriglyceridemia
usually do not undergo LDL-apheresis because the triglycer-
ides cause increased transmembrane pressure (ie, clog the
apparatus), and because of risks of clot formation and he-
molysis. However, the treatment of hypertriglyceridemia
and pancreatitis with plasmapheresis has been shown to be
effective.6,9 Although various apheresis systems have been
available for w25 years, it is included in discussions of
novel or emerging therapies for FH because it is not widely
used and may be unfamiliar to many practicing physicians.
Although, by necessity, studies of LDL-apheresis have
been small and nonrandomized, their results have been con-
sistent with major statin trials demonstrating significant re-
ductions in cardiac morbidity in both homozygous and
severe heterozygous FH populations.Candidates for LDL-apheresis
Candidates for LDL-apheresis include patients who after
6 months of maximally tolerated medications still have
markedly elevated LDL-C levels.10 The National Lipid As-
sociation Expert Panel on Familial Hypercholesterolemia
recommends consideration of LDL-apheresis in functional
homozygotes with LDL-C $300 mg/dL (or non-high-
density lipoprotein [HDL]-C $330 mg/dL), functional het-
erozygotes with LDL-C $300 mg/dL (or non-HDL-C
$330 mg/dL) and 0–1 coronary heart disease (CHD) risk
factors, functional heterozygotes with LDL-C
$200 mg/dL (or non-HDL-C $230 mg/dL) and high-risk
characteristics [$2 CHD risk factors or high Lp(a)
$50 mg/dL using an isoform insensitive assay], and func-
tional heterozygotes with LDL-C $160 mg/dL (or non-
HDL-C $190 mg/dL) and very-high-risk characteristics
(established CHD, other cardiovascular disease, or diabe-
tes).10 As a result of these recommendations, many insur-
ance carriers now pay for LDL-apheresis in functional
heterozygotes with LDL-C $160 mg/dL who have cardio-
vascular disease or cardiovascular risk equivalents.
A single LDL-apheresis procedure typically removes at
least 60% of Apo B–containing lipoproteins, but there is a
rebound and the procedure needs to be repeated frequently
(Fig. 1). For homozygote patients, once-a-week therapy is
recommended, and for heterozygotes, it is usually per-
formed every other week. There are several negative as-
pects to LDL-apheresis treatment. One of the major
issues is vascular access. For most patients, peripheral ac-
cess becomes problematic, necessitating an arteriovenous
fistula. An arteriovenous fistula is a surgically created con-
nection of a vein and an artery in the forearm to allow ac-
cess to the vascular system. Unfortunately, some patients
decline LDL-apheresis secondary to a reluctance to un-
dergo this surgical procedure. LDL-apheresis requires a
significant time commitment. Each session takes between
McGowan Emerging LDL therapies: LDL-apheresis S232 and 4 hours, during which time the patient is sitting qui-
etly. Adults receiving LDL-apheresis, or driving their chil-
dren to appointments, typically have to take at least half a
day and often a whole day off from work. Some patients are
also fatigued after the process, necessitating an additional
day off from work. To complicate this, LDL-apheresis is
not performed at most medical facilities in the United
States; people often have to travel a great distance to an
LDL-apheresis center for treatment.HELP and Liposorber systems
Plasmapheresis or complete plasma exchange was an
early precursor to the LDL-apheresis procedures used
today. Its use was first described in 1967 by de Gennes
et al11 in a patient with homozygous FH. Five individuals
with homozygous FH who underwent plasma exchange
therapy in the 1970s were reported to have longer survival
than siblings with a presumed identical defect in the LDL
receptor who died without undergoing this treatment.12–15
However, in addition to removing atherogenic lipoproteins,
complete plasma exchange also removes high-density lipo-
protein particles and other plasma proteins (eg, albumin and
immunoglobulins). Therefore, a selective process to re-
move LDL particles was developed.
In 1976, Lupien et al created a process using heparin
agarose beads for selective LDL removal.16 This was fol-
lowed in 1983 by the development of continuous heparin-
induced extracorporeal LDL precipitation (HELP)7 and inFigure 2 Liposorber system. Copyright Kaneka Pharma America, L
Pharma America, LLC.1986 by the introduction of a system using dextran sulfate
cellulose columns (Liposorber).8,17 Both systems work on
electrochemical principles. In the Liposorber system, dex-
tran sulfate binds to Apo B; in the HELP system, heparin
binds to Apo B. These two LDL-apheresis systems received
marketing approval from the United States Food and Drug
Administration: Liposorber LA-15 in 1996 and HELP in
1997. There are other systems used elsewhere in the world,
but only these two are approved in the United States.
In the Liposorber system, the patient’s blood is with-
drawn via a venous access and enters a plasma separator
(Fig. 2). As blood flows through the hollow fibers of the
separator, the plasma is separated and pumped into one of
the two LDL adsorption (Liposorber) columns. The Lipo-
sorber columns have cellulose beads impregnated with dex-
tran sulfate. As the plasma passes through the column, the
Apo B–containing lipoproteins, LDL, Lp(a) and VLDL, are
selectively adsorbed by the dextran sulfate-cellulose beads.
When the capacity of the first column is reached, flow is re-
directed to the second column while the first is regenerated.
Flow alternates between the two columns throughout treat-
ment. Treated plasma is finally combined with the previ-
ously separated red blood cells and returned to the patient
via a second venous access.
The HELP system is a similar process but has a slightly
different procedure for removing the LDL (Fig. 3). Blood is
removed, and plasma and cellular components are sepa-
rated in the plasma separator. The plasma is treated with
a heparin buffer solution at a pH of 5.12, which precipitates
the LDL. The heparin is then removed from the plasma, theLC 2010. This figure was reprinted with permission from Kaneka
Figure 3 Diagram of the HELP system. LDL, low-density lipoprotein.
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red blood cells and returned to the patient.Safety of LDL-apheresis
Safety information collected from 64 patients who
underwent 3902 LDL-apheresis treatments, in clinical trials
using the dextran cellulose adsorption system, indicated
side effects of hypotension (n 5 34, 0.9%), nausea/vom-
iting (n 5 26, 0.7%), flushing (n 5 19, 0.5%), chest pain
(n 5 10, 0.3%), fainting (n 5 9, 0.2%), lightheadedness
(n 5 7, 0.2%), and anemia (n 5 6, 0.2%).18 At the time the
early safety data were collected, it was not known that the
dextran sulfate in the Liposorber system activated the in-
trinsic pathway of coagulation which increased bradykinin,
a peptide that dilates blood vessels leading to a reduction in
blood pressure. Angiotensin-converting enzyme (ACE) in-
hibitors also increase bradykinin by inhibiting its degrada-
tion.19 Thus, concomitant use of ACE inhibitors in patients
undergoing LDL-apheresis likely contributed to the in-
creased incidence of hypotension. Currently, ACE inhibi-
tors are withheld for 24–48 hour before LDL-apheresis,
or patients are switched to an angiotensin receptor blocker.Clinical trials of LDL-apheresis
Virtually all of the studies of clinical benefit of LDL-
apheresis are nonrandomized investigations enrolling rela-
tively few patients. Although the data are not as rigorous as
statin trials, they support the benefit of LDL-C reduction for
reducing, cardiovascular events as has been shown in statinstudies. A prospective meta-analysis of data from 90,056
individuals in 14 randomized trials of statins reported that
statin therapy reduced 5 yr incidence of major coronary
events, coronary revascularization, and stroke by approxi-
mately 20% per mmol (per 38.7 mg/dL) reduction in LDL-
C.20
The LDL-Apheresis Atherosclerosis Regression Study,
conducted in the Netherlands, was an investigation of 42
men with angina and LDL-C .220 mg/dL who received
either LDL-apheresis plus lipid-lowering medications
(n 5 21) or lipid-lowering medications alone for 2 years
(n 5 21), 76% of the study sample had heterozygous FH
(homozygous FH or any secondary dyslipidemia was
excluded).21 In the LDL-apheresis group, average LDL-
C decreased from a statin-na€ıve baseline of 300 mg/dL
to 114 mg/dL (263%), time to 1 mm ST depression dur-
ing a bicycle exercise tolerance test increased from w7.5
to 11 minutes, and ST-max depression decreased from
w1.5 to 0.6 mm. In the group receiving lipid medications
alone (n 5 15), average LDL-C decreased from a statin-
na€ıve baseline of 300 mg/dL to 160 mg/dL (247%), but
the time to ST depression actually decreased over time
from w8.5 to 7.5 min, and the degree of ST segment de-
pression did not change.
The Low Density Lipoprotein-Apheresis Coronary Mor-
phology and Reserve Trial conducted in Japan, was an
investigation of 18 patients with heterozygous FH and
documented coronary artery disease who underwent bi-
weekly LDL-apheresis and received lipid-lowering medi-
cations (n 5 11) or received lipid-lowering medications
alone (n 5 7).22 Quantitative coronary angiography and in-
travascular ultrasound were performed at baseline and
McGowan Emerging LDL therapies: LDL-apheresis S251 year to evaluate minimum arterial lumen diameter and
plaque area, respectively. At baseline, LDL-C in the
LDL-apheresis group was 213 mg/dL compared with
174 mg/dL in the group receiving lipid medications alone.
After treatment, LDL-C decreased to 140 mg/dL (time av-
eraged, representing a 34% reduction) in the LDL-apheresis
group compared with an end-of-treatment average of
181 mg/dL in the lipid medications alone group. In the
LDL-apheresis group, minimal lumen diameter increased
significantly and plaque area decreased significantly com-
pared with the lipid medications only group. Of note, at
the time of these trials, in Japan the maximum approved
doses of pravastatin and simvastatin were 20 and 10 mg, re-
spectively. So, the medications used in this trial were less
aggressive than the lipid-lowering medications prescribed
in the United States.
In another study conducted in Japan, 130 patients with
heterozygous FH and angiographically documented CHD
were treated with either LDL-apheresis plus lipid-lowering
medications (n 5 43) or lipid-lowering medications alone
(n 5 87; Fig. 4).23 Patients were followed for 6 years and
evaluated for the composite end point of coronary events,
including nonfatal myocardial infarction (MI), percutane-
ous transluminal coronary angioplasty, coronary artery by-
pass graft, and death from CHD. Although the two
treatment groups were not randomized, patients were rea-
sonably well-matched in baseline characteristics, with the
exception of more smokers in the medications only treat-
ment arm vs. the group that also received LDL-apheresis.
Statin, probucol, bile acid sequestrants, and fibrate use at
baseline and during the trial were similar between treat-
ments. Mean baseline LDL-C concentration was greater
in the group slated for LDL-apheresis (288 mg/dL) com-
pared with those taking medications alone (234 mg/dL);
mean HDL-C and triglyceride levels at baseline were
well-matched. In the LDL-apheresis group, LDL-C de-
creased by 58% to a time-averaged level of 122 mg/dL,
and in the medications only group, LDL-C decreased by
28% to 168 mg/dL. At the end of the 6-year observation pe-
riod, 90% of LDL-apheresis patients vs. 64% of theFigure 4 Kaplan-Meier curves for the proportion of patients
without coronary events receiving LDL-apheresis in combination
with lipid-lowering medications or medications alone. Reprinted
with permission from Mabuchi et al.23 LDL, low-density
lipoprotein.medications only patients were free from major coronary
events, representing a 72% reduced risk of having an event
in the LDL-apheresis group. A subgroup analysis demon-
strated that the benefit was maintained even if smokers
were eliminated: 94% of LDL-apheresis patients and 61%
of lipid medications only patients were free from major cor-
onary events, representing an 85% reduction in the LDL-
apheresis group.
In a U.S. trial of patients with homozygous FH (n 5 10)
and heterozygous FH (n 5 54), the number of coronary
events (ie, coronary revascularization, angioplasty, ather-
ectomy, coronary artery bypass graft, MI, and cerebrovas-
cular events) during the 5 years before initiation of
LDL-apheresis (lipid-lowering medications alone) was de-
termined retrospectively through chart review and com-
pared to the number of coronary events during two and
one-half years of LDL-apheresis therapy.18 Average LDL-C
concentration among homozygotes when receiving lipid-
lowering medications alone was 480 mg/dL and in hetero-
zygotes, LDL-C was 240 mg/dL. LDL-apheresis resulted in
a 38% reduction in time-averaged LDL-C. During the
5 years before LDL-apheresis, patients had an event rate
of 6.3 per 1000 months vs. 3.5 per 1000 months in the sub-
sequent two and one-half years of LDL-apheresis—a 44%
reduction. Another long-term study of LDL-apheresis con-
ducted in Germany reported that in the 12 years before
LDL-apheresis in 180 patients with heterozygous FH and
known CHD, there were 4.5 MIs per year compared with
one MI per year in the 4 years of treatment with LDL-
apheresis–a 78% reduction.24Conclusion
In summary, LDL-apheresis is a Food and Drug Ad-
ministration–approved therapy for patients with homozy-
gous FH and severe heterozygous FH. It selectively
removes LDL, Lp(a), and VLDL particles, acutely lowering
LDL-C by 70%–80%. Although there is a rebound effect,
when repeated once-a-week in patients with homozygous
FH and every other week in patients with heterozygous FH,
it typically produces a time-average LDL-C reduction of
w40%. Unlike plasmapheresis, LDL-apheresis has no
detrimental effects on HDL, albumin, or immunoglobulin
levels. Although there are no randomized controlled out-
come trials of LDL-apheresis, available clinical data indi-
cate that the cardiovascular benefit associated with its use is
concordant with that demonstrated for other major lipid-
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